NEW ORLEANS, La., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MicroBiome Therapeutics, LLC (MBT), a leading company applying the science of the gastrointestinal (GI) microbiome to promote health and wellness, today announced completion of a Series B financing that raised approximately $1 million. MBT intends to use the proceeds to launch its clinically-tested microbiome modulator product in 2018. This unique dietary supplement is specifically designed to balance and optimize the GI tract and promote healthy metabolism by nourishing and nurturing the growth of healthful gut bacteria. New and existing investors included Lagniappe Angels, NO/LA Angel Network, Zehnder Communications and other private investors.
“We appreciate the support of our investors, which will enable the planned launch of our lead microbiome modulator next year,” said Dale Pfost, Acting CEO of MBT. “This product is a scientific formulation of natural ingredients designed to support a balanced GI microbiome and promote metabolic health, in an easy-to-use, flavorful drink mix. Our two clinical trials, conducted at the Pennington Biomedical Research Center and reported in peer-reviewed publications, demonstrated its benefits in helping to manage hunger, maintain healthy blood sugar levels and promote regularity.”
The product is an all-natural blend of prebiotics, including fermentable fiber and polyphenol antioxidants in a patent-pending blend intended to help nurture and nourish beneficial microorganisms in the lower gut.
MBT reported that the launch of its microbiome modulator will be supported by a two-year e-commerce and social media campaign conducted in partnership with New Orleans-based advertising agency Zehnder Communications. MBT is also assembling a nationwide network of registered dietitians and certified diabetic educators to support the launch.
“With MicroBiome Therapeutics, we saw a unique opportunity to apply our product launch expertise in support of an exciting, first-in-class product from a leading science-based company. We believe our expertise, along with our integrative and analytical approaches, will enable MBT to inform and educate consumers about this exciting new type of health-promoting dietary supplement. Our investment reinforces our commitment to making a difference by playing a part in the microbiome revolution,” said Jeremy Hunnewell, CFO and Business Strategist for Zehnder Communications. Hunnewell will be joining the board of directors of MBT.
About MicroBiome Therapeutics
MicroBiome Therapeutics LLC (MBT) is developing products aimed at promoting healthy metabolism by altering microbial activity and the environment in the gut to help balance and optimize the GI tract. MBT’s microbiome modulators are specifically designed to nourish and nurture the growth of healthful gut bacteria. MBT’s first product is a unique dietary supplement that has been tested in two clinical trials and will be launched in 2018. For more information, visit mbiome.com, or contact gpfost@mbiome.com.
About Lagniappe Angels
Lagniappe Angels is a committed capital angel investment group based in New Orleans, Louisiana which invests in early-stage local companies with the potential for rapid growth. The group is 'member managed' meaning that our investors actively participate in the investment process and make all investment decisions. 'Committed capital' means that investors pay in capital on a fixed schedule and share pro rata in the economic outcomes of the group's investments. As a member-driven organization, the group is professional and disciplined while remaining approachable. For more information, visit lagniappeangels.com/.
About NO/LA Angel Network
The NO/LA Angel Network is a group of accredited investors from New Orleans and throughout Louisiana who work together to evaluate, fund and nurture early-stage companies. Members make individual decisions to invest in high growth Louisiana based businesses, where the path to exit is understood. For more information, visit nolaangelnetwork.org/.
About Zehnder Communications
Zehnder Communications is a fully integrated advertising agency, providing strategic marketing, business intelligence, product launch consulting, creative services, media placement, social media, public relations, research and analytics, interactive design and programming. With offices in New Orleans, Nashville and Baton Rouge, Zehnder has served the greater Southeast region for 20 years. For more information, visit z-comm.com/.
Contacts:
MicroBiome Therapeutics
Gertrude Pfost
Director of Business Development
gpfost@mbiome.com
Media:
BLL Partners, LLC
Barbara Lindheim
+1 212 584-2276
blindheim@bllbiopartners.com